Iovance | search
Click here to view Iovance news from 60+ newspapers.
Bookmark or Share- FDA approves first T-cell therapy for a solid tumorIovance is pricing the one-time treatment at a wholesale acquisition cost of $515,000 per patient, the company’s interim CEO Frederick Vogt, Ph.D., said on a call following Friday’s approval.
- Our Investigational TIL Therapy – Iovance BiotherapeuticsIovance is developing tumor infiltrating lymphocyte (TIL) therapy as monotherapy and as part of combination therapy in clinical trials of multiple advanced solid tumor cancers including melanoma, non-small cell lung cancer and cervical cancer.
- Investigating TIL Therapy & PBL Therapy for Cancer - Iovance ...Learn about our investigational tumor infiltrating lymphocyte (TIL) therapy and peripheral blood lymphocyte (PBL) therapy. View our clinical trials and pipeline.
- Iovance: Approval For Solid Tumor Targeting TIL Therapy Likely, Outlook ...Iovance's tumor infiltrating lymphocyte cell therapy candidate, lifileucel, has shown promising results in a study of melanoma patients, with a 31.4% overall response rate.
- Behind the breakthrough cancer therapy that just won a historic FDA nodA long development road has paid off for Iovance Biotherapeutics, which recently won an accelerated approval for the first cell therapy to treat advanced melanoma. The FDA OK will also swing the door open to a promising type of immunotherapy for solid tumors.
More
